Monoclonal Antibodies Market Size, Share & Trends Analysis Report By Source Type (Chimeric, Murine, Humanized, Human), By Production Type (In Vivo, In Vitro), By Application, By End-use, By Region, And Segment Forecasts, 2023 - 2030

Table of Contents

Chapter 1. Methodology and Scope
                    1.1. Information Procurement
                    1.2. Information or Data Analysis
                    1.3. Market Scope & Segment Definition
                    1.4. Market Model
                         1.4.1. Market Study, By Company Market Share
                         1.4.2. Regional Analysis
Chapter 2. Executive Summary
                    2.1. Market Snapshot
                    2.2. Segment Snapshot
                    2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
                    3.1. Market Segmentation and Scope
                    3.2. Market Lineage Outlook
                         3.2.1. Parent Market Outlook
                         3.2.2. Related/Ancillary Market Outlook
                    3.3. Market Dynamics
                         3.3.1. Market Driver Analysis
                             3.3.1.1. Increasing Incidences Of Chronic Diseases
                             3.3.1.2. Technological Advancements
                             3.3.1.3. Growing Awareness Levels
                         3.3.2. Market Restraint Analysis
                             3.3.2.1. High Cost Of Therapeutic Mabs
                    3.4. Industry Analysis Tools
                         3.4.1. SWOT Analysis; By Factor (Political & Legal, Economic And Technological)
                         3.4.2. Porter's Five Forces Analysis
                         3.4.3. Penetration and Growth Prospect Mapping, 2022
                    3.5. COVID-19 Impact Analysis
Chapter 4. Monoclonal Antibodies Market: Source Type Business Analysis
                    4.1. Monoclonal Antibodies Market: Source Type Movement Analysis
                    4.2. Murine
                         4.2.1. Global Murine Market, 2018 - 2030 (USD Million)
                    4.3. Chimeric
                         4.3.1. Global Chimeric Market, 2018 - 2030 (USD Million)
                    4.4. Humanized
                         4.4.1. Global Humanized Market, 2018 - 2030 (USD Million)
                    4.5. Human
                         4.5.1. Global Human Market, 2018 - 2030 (USD Million)
Chapter 5. Monoclonal Antibodies Market: Production Type Business Analysis
                    5.1. Monoclonal Antibodies Market: Production Type Movement Analysis
                    5.2. In Vivo
                         5.2.1. Global In Vivo Market, 2018 - 2030 (USD Million)
                    5.3. In Vitro
                         5.3.1. Global In Vitro Market, 2018 - 2030 (USD Million)
Chapter 6. Monoclonal Antibodies Market: Application Business Analysis
                    6.1. Monoclonal Antibodies Market: Application Movement Analysis
                    6.2. Oncology
                         6.2.1. Global Oncology Market, 2018 - 2030 (USD Million)
                    6.3. Autoimmune Diseases
                         6.3.1. Global Autoimmune Diseases Market, 2018 - 2030 (USD Million)
                    6.4. Infectious Diseases
                         6.4.1. Global Infectious Diseases Market, 2018 - 2030 (USD Million)
                    6.5. Neurological Diseases
                         6.5.1. Global Neurological Diseases Market, 2018 - 2030 (USD Million)
                    6.6. Others
                         6.6.1. Global Others Market, 2018 - 2030 (USD Million)
Chapter 7. Monoclonal Antibodies Market: End-use Business Analysis
                    7.1. Monoclonal Antibodies Market: End-use Movement Analysis
                    7.2. Hospitals
                         7.2.1. Global Hospitals Market, 2018 - 2030 (USD Million)
                    7.3. Specialty centers
                         7.3.1. Global Specialty Centers Market, 2018 - 2030 (USD Million)
                    7.4. Others
                         7.4.1. Global Others Market, 2018 - 2030 (USD Million)
Chapter 8. Monoclonal Antibodies Market: Regional Business Analysis
                    8.1. Monoclonal Antibodies Market Share By Region, 2022 & 2030
                    8.2. North America
                         8.2.1. North America Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
                         8.2.2. U.S.
                             8.2.2.1. Key Country Dynamics
                             8.2.2.2. Competitive Scenario
                             8.2.2.3. Regulatory Framework
                             8.2.2.4. U.S. Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
                         8.2.3. Canada
                             8.2.3.1. Key Country Dynamics
                             8.2.3.2. Competitive Scenario
                             8.2.3.3. Regulatory Framework
                             8.2.3.4. Canada Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
                    8.3. Europe
                         8.3.1. Europe Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
                         8.3.2. UK
                             8.3.2.1. Key Country Dynamics
                             8.3.2.2. Competitive Scenario
                             8.3.2.3. Regulatory Framework
                             8.3.2.4. UK Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
                         8.3.3. Germany
                             8.3.3.1. Key Country Dynamics
                             8.3.3.2. Competitive Scenario
                             8.3.3.3. Regulatory Framework
                             8.3.3.4. Germany Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
                         8.3.4. France
                             8.3.4.1. Key Country Dynamics
                             8.3.4.2. Competitive Scenario
                             8.3.4.3. Regulatory Framework
                             8.3.4.4. France Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
                         8.3.5. Italy
                             8.3.5.1. Key Country Dynamics
                             8.3.5.2. Competitive Scenario
                             8.3.5.3. Regulatory Framework
                             8.3.5.4. Italy Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
                         8.3.6. Spain
                             8.3.6.1. Key Country Dynamics
                             8.3.6.2. Competitive Scenario
                             8.3.6.3. Regulatory Framework
                             8.3.6.4. Spain Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
                         8.3.7. Denmark
                             8.3.7.1. Key Country Dynamics
                             8.3.7.2. Competitive Scenario
                             8.3.7.3. Regulatory Framework
                             8.3.7.4. Denmark Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
                         8.3.8. Sweden
                             8.3.8.1. Key Country Dynamics
                             8.3.8.2. Competitive Scenario
                             8.3.8.3. Regulatory Framework
                             8.3.8.4. Sweden Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
                         8.3.9. Norway
                             8.3.9.1. Key Country Dynamics
                             8.3.9.2. Competitive Scenario
                             8.3.9.3. Regulatory Framework
                             8.3.9.4. Norway Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
                    8.4. Asia Pacific
                         8.4.1. Asia Pacific Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
                         8.4.2. Japan
                             8.4.2.1. Key Country Dynamics
                             8.4.2.2. Competitive Scenario
                             8.4.2.3. Regulatory Framework
                             8.4.2.4. Japan Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
                         8.4.3. China
                             8.4.3.1. Key Country Dynamics
                             8.4.3.2. Competitive Scenario
                             8.4.3.3. Regulatory Framework
                             8.4.3.4. China Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
                         8.4.4. India
                             8.4.4.1. Key Country Dynamics
                             8.4.4.2. Competitive Scenario
                             8.4.4.3. Regulatory Framework
                             8.4.4.4. India Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
                         8.4.5. Australia
                             8.4.5.1. Key Country Dynamics
                             8.4.5.2. Competitive Scenario
                             8.4.5.3. Regulatory Framework
                             8.4.5.4. Australia Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
                         8.4.6. Thailand
                             8.4.6.1. Key Country Dynamics
                             8.4.6.2. Competitive Scenario
                             8.4.6.3. Regulatory Framework
                             8.4.6.4. Thailand Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
                         8.4.7. South Korea
                             8.4.7.1. Key Country Dynamics
                             8.4.7.2. Competitive Scenario
                             8.4.7.3. Regulatory Framework
                             8.4.7.4. South Korea Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
                    8.5. Latin America
                         8.5.1. Latin America Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
                         8.5.2. Brazil
                             8.5.2.1. Key Country Dynamics
                             8.5.2.2. Competitive Scenario
                             8.5.2.3. Regulatory Framework
                             8.5.2.4. Brazil Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
                         8.5.3. Mexico
                             8.5.3.1. Key Country Dynamics
                             8.5.3.2. Competitive Scenario
                             8.5.3.3. Regulatory Framework
                             8.5.3.4. Mexico Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
                         8.5.4. Argentina
                             8.5.4.1. Key Country Dynamics
                             8.5.4.2. Competitive Scenario
                             8.5.4.3. Regulatory Framework
                             8.5.4.4. Argentina Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
                    8.6. MEA
                         8.6.1. MEA Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
                         8.6.2. South Africa
                             8.6.2.1. Key Country Dynamics
                             8.6.2.2. Competitive Scenario
                             8.6.2.3. Regulatory Framework
                             8.6.2.4. South Africa Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
                         8.6.3. Saudi Arabia
                             8.6.3.1. Key Country Dynamics
                             8.6.3.2. Competitive Scenario
                             8.6.3.3. Regulatory Framework
                             8.6.3.4. Saudi Arabia Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
                         8.6.4. UAE
                             8.6.4.1. Key Country Dynamics
                             8.6.4.2. Competitive Scenario
                             8.6.4.3. Regulatory Framework
                             8.6.4.4. UAE Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
                         8.6.5. Kuwait
                             8.6.5.1. Key Country Dynamics
                             8.6.5.2. Competitive Scenario
                             8.6.5.3. Regulatory Framework
                             8.6.5.4. Kuwait Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
                         8.6.6. Kenya
                             8.6.6.1. Key Country Dynamics
                             8.6.6.2. Competitive Scenario
                             8.6.6.3. Regulatory Framework
                             8.6.6.4. Kenya Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
                         8.6.7. Zimbabwe
                             8.6.7.1. Key Country Dynamics
                             8.6.7.2. Competitive Scenario
                             8.6.7.3. Regulatory Framework
                             8.6.7.4. Zimbabwe Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
                         8.6.8. Egypt
                             8.6.8.1. Key Country Dynamics
                             8.6.8.2. Competitive Scenario
                             8.6.8.3. Regulatory Framework
                             8.6.8.4. Egypt Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
                         8.6.9. Nigeria
                             8.6.9.1. Key Country Dynamics
                             8.6.9.2. Competitive Scenario
                             8.6.9.3. Regulatory Framework
                             8.6.9.4. Nigeria Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
                         8.6.10. Morocco
                             8.6.10.1. Key Country Dynamics
                             8.6.10.2. Competitive Scenario
                             8.6.10.3. Regulatory Framework
                             8.6.10.4. Morocco Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
                         8.6.11. Algeria
                             8.6.11.1. Key Country Dynamics
                             8.6.11.2. Competitive Scenario
                             8.6.11.3. Regulatory Framework
                             8.6.11.4. Algeria Monoclonal Antibodies Market, 2018 - 2030 (USD Million)
Chapter 9. Competitive Landscape
                    9.1. Company Categorization
                    9.2. Strategy Mapping
                    9.3. Company Profiles/Listing
                         9.3.1. Novartis AG
                             9.3.1.1. Overview
                             9.3.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                             9.3.1.3. Product Benchmarking
                             9.3.1.4. Strategic Initiatives
                         9.3.2. Pfizer Inc
                             9.3.2.1. Overview
                             9.3.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                             9.3.2.3. Product Benchmarking
                             9.3.2.4. Strategic Initiatives
                         9.3.3. GlaxoSmithKline plc
                             9.3.3.1. Overview
                             9.3.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                             9.3.3.3. Product Benchmarking
                             9.3.3.4. Strategic Initiatives
                         9.3.4. Amgen Inc.
                             9.3.4.1. Overview
                             9.3.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                             9.3.4.3. Product Benchmarking
                             9.3.4.4. Strategic Initiatives
                         9.3.5. Merck & Co., Inc.
                             9.3.5.1. Overview
                             9.3.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                             9.3.5.3. Product Benchmarking
                             9.3.5.4. Strategic Initiatives
                         9.3.6. Daiichi Sankyo Company, Limited
                             9.3.6.1. Overview
                             9.3.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                             9.3.6.3. Product Benchmarking
                             9.3.6.4. Strategic Initiatives
                         9.3.7. Abbott Laboratories
                             9.3.7.1. Overview
                             9.3.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                             9.3.7.3. Product Benchmarking
                             9.3.7.4. Strategic Initiatives
                         9.3.8. AstraZeneca plc
                             9.3.8.1. Overview
                             9.3.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                             9.3.8.3. Product Benchmarking
                             9.3.8.4. Strategic Initiatives
                         9.3.9. Eli Lilly And Company
                             9.3.9.1. Overview
                             9.3.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                             9.3.9.3. Product Benchmarking
                             9.3.9.4. Strategic Initiatives
                         9.3.10. Johnson & Johnson Services, Inc.
                             9.3.10.1. Overview
                             9.3.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                             9.3.10.3. Product Benchmarking
                             9.3.10.4. Strategic Initiatives
                         9.3.11. Bayer AG
                             9.3.11.1. Overview
                             9.3.11.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                             9.3.11.3. Product Benchmarking
                             9.3.11.4. Strategic Initiatives
                         9.3.12. Bristol Myers Squibb
                             9.3.12.1. Overview
                             9.3.12.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                             9.3.12.3. Product Benchmarking
                             9.3.12.4. Strategic Initiatives
                         9.3.13. F. Hoffman-La Roche Ltd.
                             9.3.13.1. Overview
                             9.3.13.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                             9.3.13.3. Product Benchmarking
                             9.3.13.4. Strategic Initiatives
                         9.3.14. Viatris Inc.
                             9.3.14.1. Overview
                             9.3.14.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                             9.3.14.3. Product Benchmarking
                             9.3.14.4. Strategic Initiatives
                         9.3.15. Biogen Inc.
                             9.3.15.1. Overview
                             9.3.15.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                             9.3.15.3. Product Benchmarking
                             9.3.15.4. Strategic Initiatives
                         9.3.16. Thermo Fisher Scientific, Inc.
                             9.3.16.1. Overview
                             9.3.16.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                             9.3.16.3. Product Benchmarking
                             9.3.16.4. Strategic Initiatives
                         9.3.17. Novo Nordisk A/S
                             9.3.17.1. Overview
                             9.3.17.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                             9.3.17.3. Product Benchmarking
                             9.3.17.4. Strategic Initiatives
                         9.3.18. Sanofi S.A.
                             9.3.18.1. Overview
                             9.3.18.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                             9.3.18.3. Product Benchmarking
                             9.3.18.4. Strategic Initiatives
                         9.3.19. Merck KGaA
                             9.3.19.1. Overview
                             9.3.19.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                             9.3.19.3. Product Benchmarking
                             9.3.19.4. Strategic Initiatives

List of Tables

Table 1 Global monoclonal antibodies market, by region, 2018 - 2030 (USD Billion)
Table 2 Global monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 3 Global monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 4 Global monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 5 Global monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 6 North America monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 7 North America monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 8 North America monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 9 North America monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 10 U.S. monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 11 U.S. monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 12 U.S. monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 13 U.S. monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 14 Canada monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 15 Canada monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 16 Canada monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 17 Canada monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 18 Europe monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 19 Europe monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 20 Europe monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 21 Europe monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 22 UK monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 23 UK monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 24 UK monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 25 UK monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 26 Germany monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 27 Germany monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 28 Germany monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 29 Germany monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 30 France monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 31 France monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 32 France monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 33 France monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 34 Italy monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 35 Italy monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 36 Italy monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 37 Italy monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 38 Spain monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 39 Spain monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 40 Spain monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 41 Spain monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 42 Sweden monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 43 Sweden monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 44 Sweden monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 45 Sweden monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 46 Denmark monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 47 Denmark monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 48 Denmark monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 49 Denmark monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 50 Norway monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 51 Norway monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 52 Norway monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 53 Norway monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 54 Asia Pacific monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 55 Asia Pacific monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 56 Asia Pacific monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 57 Asia Pacific monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 58 Japan monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 59 Japan monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 60 Japan monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 61 Japan monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 62 China monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 63 China monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 64 China monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 65 China monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 66 India monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 67 India monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 68 India monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 69 India monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 70 Australia monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 71 Australia monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 72 Australia monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 73 Australia monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 74 South Korea monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 75 South Korea monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 76 South Korea monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 77 South Korea monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 78 Thailand monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 79 Thailand monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 80 Thailand monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 81 Thailand monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 82 Latin America monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 83 Latin America monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 84 Latin America monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 85 Latin America monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 86 Brazil monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 87 Brazil monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 88 Brazil monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 89 Brazil monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 90 Mexico monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 91 Mexico monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 92 Mexico monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 93 Mexico monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 94 Argentina monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 95 Argentina monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 96 Argentina monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 97 Argentina monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 98 Middle East & Africa monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 99 Middle East & Africa monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 100 Middle East & Africa monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 101 Middle East & Africa monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 102 South Africa monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 103 South Africa monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 104 South Africa monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 105 South Africa monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 106 Saudi Arabia monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 107 Saudi Arabia monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 108 Saudi Arabia monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 109 Saudi Arabia monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 110 UAE monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 111 UAE monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 112 UAE monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 113 UAE monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 114 Kuwait monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 115 Kuwait monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 116 Kuwait monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 117 Kuwait monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 118 Kenya monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 119 Kenya monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 120 Kenya monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 121 Kenya monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 122 Zimbabwe monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 123 Zimbabwe monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 124 Zimbabwe monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 125 Zimbabwe monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 126 Egypt monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 127 Egypt monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 128 Egypt monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 129 Egypt monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 130 Nigeria monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 131 Nigeria monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 132 Nigeria monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 133 Nigeria monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 134 Morocco monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 135 Morocco monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 136 Morocco monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 137 Morocco monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)
Table 138 Algeria monoclonal antibodies market, by source type, 2018 - 2030 (USD Billion)
Table 139 Algeria monoclonal antibodies market, by production type, 2018 - 2030 (USD Billion)
Table 140 Algeria monoclonal antibodies market, by application, 2018 - 2030 (USD Billion)
Table 141 Algeria monoclonal antibodies market, by end-use, 2018 - 2030 (USD Billion)

List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value chain-based sizing & forecasting
Fig. 6 Market formulation & validation
Fig. 7 Monoclonal antibodies market segmentation
Fig. 8 Market driver relevance analysis (current & future impact)
Fig. 9 Market restraint relevance analysis (current & future impact)
Fig. 10 Penetration & growth prospect mapping
Fig. 11 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 12 Porter’s five forces analysis
Fig. 13 Market penetration vs growth prospect mapping
Fig. 14 Monoclonal antibodies market: Source type outlook and key takeaways
Fig. 15 Monoclonal antibodies market: Source type movement analysis
Fig. 16 Murine market, 2018 - 2030 (USD Billion)
Fig. 17 Chimeric market, 2018 - 2030 (USD Billion)
Fig. 18 Humanized market, 2018 - 2030 (USD Billion)
Fig. 19 Human market, 2018 - 2030 (USD Billion)
Fig. 20 Monoclonal antibodies market: Production type outlook and key takeaways
Fig. 21 Monoclonal antibodies market: Production type movement analysis
Fig. 22 In vivo market, 2018 - 2030 (USD Billion)
Fig. 23 In vitro market, 2018 - 2030 (USD Billion)
Fig. 24 Monoclonal antibodies market: Application outlook and key takeaways
Fig. 25 Monoclonal antibodies market: Application movement analysis
Fig. 26 Oncology market, 2018 - 2030 (USD Billion)
Fig. 27 Autoimmune diseases market, 2018 - 2030 (USD Billion)
Fig. 28 Infectious diseases market, 2018 - 2030 (USD Billion)
Fig. 29 Neurological diseases market, 2018 - 2030 (USD Billion)
Fig. 30 Other applications, 2018 - 2030 (USD Billion)
Fig. 31 Monoclonal antibodies market: End-use outlook and key takeaways
Fig. 32 Monoclonal antibodies market: End-use movement analysis
Fig. 33 Hospitals market, 2018 - 2030 (USD Billion)
Fig. 34 Specialty centres, 2018 - 2030 (USD Billion)
Fig. 35 Other end-use market, 2018 - 2030 (USD Billion)
Fig. 36 Regional market: Key takeaways
Fig. 37 Regional outlook, 2018 & 2030
Fig. 38 North America monoclonal antibodies market, 2018 - 2030 (USD Billion)
Fig. 39 U.S. monoclonal antibodies market, 2018 - 2030 (USD Billion)
Fig. 40 Canada monoclonal antibodies market, 2018 - 2030 (USD Billion)
Fig. 41 Europe monoclonal antibodies market, 2018 - 2030 (USD Billion)
Fig. 42 UK monoclonal antibodies market, 2018 - 2030 (USD Billion)
Fig. 43 Germany monoclonal antibodies market, 2018 - 2030 (USD Billion)
Fig. 44 France monoclonal antibodies market, 2018 - 2030 (USD Billion)
Fig. 45 Italy monoclonal antibodies market, 2018 - 2030 (USD Billion)
Fig. 46 Spain monoclonal antibodies market, 2018 - 2030 (USD Billion)
Fig. 47 Denmark monoclonal antibodies market, 2018 - 2030 (USD Billion)
Fig. 48 Norway monoclonal antibodies market, 2018 - 2030 (USD Billion)
Fig. 49 Sweden monoclonal antibodies market, 2018 - 2030 (USD Billion)
Fig. 50 Asia Pacific monoclonal antibodies market, 2018 - 2030 (USD Billion)
Fig. 51 Japan monoclonal antibodies market, 2018 - 2030 (USD Billion)
Fig. 52 China monoclonal antibodies market, 2018 - 2030 (USD Billion)
Fig. 53 India monoclonal antibodies market, 2018 - 2030 (USD Billion)
Fig. 54 Australia monoclonal antibodies market, 2018 - 2030 (USD Billion)
Fig. 55 Thailand monoclonal antibodies market, 2018 - 2030 (USD Billion)
Fig. 56 South Korea monoclonal antibodies market, 2018 - 2030 (USD Billion)
Fig. 57 Latin America monoclonal antibodies market, 2018 - 2030 (USD Billion)
Fig. 58 Brazil monoclonal antibodies market, 2018 - 2030 (USD Billion)
Fig. 59 Mexico monoclonal antibodies market, 2018 - 2030 (USD Billion)
Fig. 60 Argentina monoclonal antibodies market, 2018 - 2030 (USD Billion)
Fig. 61 MEA monoclonal antibodies market, 2018 - 2030 (USD Billion)
Fig. 62 South Africa monoclonal antibodies market, 2018 - 2030 (USD Billion)
Fig. 63 Saudi Arabia monoclonal antibodies market, 2018 - 2030 (USD Billion)
Fig. 64 UAE monoclonal antibodies market, 2018 - 2030 (USD Billion)
Fig. 65 Kuwait monoclonal antibodies market, 2018 - 2030 (USD Billion)
Fig. 66 Kenya monoclonal antibodies market, 2018 - 2030 (USD Billion)
Fig. 67 Zimbabwe monoclonal antibodies market, 2018 - 2030 (USD Billion)
Fig. 68 Egypt monoclonal antibodies market, 2018 - 2030 (USD Billion)
Fig. 69 Nigeria monoclonal antibodies market, 2018 - 2030 (USD Billion)
Fig. 70 Morocco monoclonal antibodies market, 2018 - 2030 (USD Billion)
Fig. 71 Algeria monoclonal antibodies market, 2018 - 2030 (USD Billion)